Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

We are proud to announce that OMF has funded the establishment of a third ME / CFS Collaborative Research Center, at Uppsala University in Sweden.

Jonas Bergquist, MD, PhD, in the Uppsala University lab.

The new Uppsala Center will be led by OMF Scientific Advisory Board member Jonas Bergquist, MD, PhD, and will work synergistically with the ME / CFS Collaborative Research Center at Stanford led by Ronald W. Davis, PhD, and the ME / CFS Collaborative Research Center at Massachusetts General Hospital and Harvard Affiliated Hospitals, led by Ronald G. Tompkins, MD, ScD, and Wenzhong Xiao, PhD, of Harvard University. All science funded by OMF continues to be under the overall direction of our Scientific Advisory Board, directed by Ron Davis.

This new Collaborative Center focuses on the targeted molecular diagnosis of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) with the goal of evidence-based strategies for interventions. In Uppsala, significant efforts are being brought to bear on the analysis of cerebrospinal fluid as a unique source of neurochemical biomarkers of ME / CFS. High-resolution mass spectrometry will be used for extremely sensitive detection of endogenous biomolecules. This unique technology, in combination with the development of clinically relevant screening and targeted methods for sampling, will deliver previously unattainable insights into the pathophysiology of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS).

Uppsala University, Sweden
Jonas Bergquist, MD, PhD, Prof, Director
Kumari Ubhayasekhera, PhD
Annie Bynke, Med Student
Rizwan Muhammad, Guest Researcher
N.N. PhD Student
Torsten Gordh, MD, PhD, Prof em

Karolinska Institutet

Per Julin, MD, PhD

Anders Rehnström, PhD

Anna Lindquist, MD

Emelie Karlsson, RN

Bragee Clinics, Sweden

Bo C. Bertilsson, MD, PhD

Björn Bragée, MD

Gunnar Olsson, MD, PhD

Jonas Axelsson, MD, PhD

Britt Bragée, RPT, PhD

Gabriella Bernhoff, RPT, PhD student

Brandon Drum, Med Student

Michael Fahlqvist, MD – internship

Michos Anastasios, MD

Gottfries Clinic

CG Gottfries, MD, PhD

Linkoping University

Anders Rosén, MD, PhD

Björn Ingelsson, PhD

Eirini Apostoulo, PhD

Charite

Carmen Scheibenbogen, MD, PhD

University of East Anglia

Simon Carding, PhD

Learn more about the  ME / CFS Collaborative Research Center at Uppsala University here.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 
 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo